Rezolute (NASDAQ:RZLT) said the FDA is continuing its review of additional Phase 3 sunRIZE data for ersodetug in congenital hyperinsulinism after the study failed to meet its primary endpoint, leaving the potential regulatory path unresolved and without a specific timeline for agency feedback.
Key Investor Takeaways
- The FDA review remains ongoing as the agency evaluates whether there is a potential regulatory path forward for ersodetug in congenital hyperinsulinism.
- Rezolute (NASDAQ:RZLT) submitted additional datasets and analyses after the Phase 3 sunRIZE study failed to achieve statistically significant results for its primary endpoint.
- The company reported consistent improvements versus placebo across multiple continuous glucose monitoring measures, including 50% or greater reductions in certain hypoglycemia metrics at both dose levels.
- No timeline has been established for FDA feedback because the review is taking place outside the customary formal meeting process.
- A separate Phase 3 catalyst remains ahead, with topline results from the upLIFT study of ersodetug in tumor hyperinsulinism expected before the end of 2026.
Why RZLT Stock Is in Focus
Rezolute’s regulatory discussions with the FDA remain active despite the Phase 3 sunRIZE study failing its primary and key secondary endpoints.
The 63-patient study evaluated two doses of ersodetug against placebo in patients with congenital hyperinsulinism. While hypoglycemia events declined from baseline, the primary endpoint did not demonstrate a statistically significant improvement versus placebo.
Following a Type B meeting in March 2026, the FDA requested additional study information for an independent review. Rezolute subsequently submitted source and analysis datasets in June, together with results from numerous pre-specified, post-hoc and sensitivity analyses focused particularly on continuous glucose monitoring, or CGM.
According to Rezolute, both ersodetug dose groups showed consistent glycemic improvements compared with placebo across multiple CGM measures. These included reductions of at least 50% in average daily percentage of time spent in hypoglycemia and average weekly hypoglycemia events.
The FDA has since reiterated that its review is continuing as it considers a potential regulatory path forward. However, Rezolute said there is currently no specific timetable for receiving feedback or reaching agreement on next steps.
Why This Matters for Investors
The FDA review keeps the congenital hyperinsulinism programme active despite the pivotal trial miss, but it does not establish that the additional analyses will be sufficient to support a regulatory filing or another development pathway.
That distinction is central for investors. Rezolute believes the submitted data provide potential evidence of target engagement, pharmacologic activity and glycemic improvement, but those interpretations remain subject to the FDA’s independent assessment.
The ongoing open-label extension provides additional information on longer-term use. Participants have accumulated approximately nine months to more than two years of ersodetug treatment, with the company reporting high retention, continued glycemic monitoring and reduced use of background standard-of-care therapies.
These observations may contribute to the overall clinical dataset, but the immediate regulatory uncertainty remains tied to how the FDA interprets the Phase 3 results and supporting analyses after the original primary and key secondary endpoints were missed.
Rezolute retains the option of requesting a formal FDA meeting under an established regulatory timeline if needed, providing another possible route to clarify the programme’s next steps.
What to Watch Next
The most important congenital hyperinsulinism catalyst is FDA feedback on the additional sunRIZE analyses and whether the agency identifies a viable regulatory path for ersodetug.
Investors can also watch for any decision by Rezolute to request a formal FDA meeting if the current review does not produce sufficient clarity.
Separately, the Phase 3 upLIFT study in tumor hyperinsulinism continues to recruit patients, with Rezolute maintaining its target of reporting topline results before the end of 2026.